CD275 [B7-H2] (human):Fc (human) (rec.) (non-lytic)
|Synonyms||B7-H2; ICOS Ligand; B7-like Protein Gl50; B7RP-1|
The extracellular domain of human CD275 [B7-H2] (aa 1-256) is fused to the N-terminus of the Fc region of a mutant human IgG1.
Acts as a long lasting fusion protein which only binds to the receptor. Mutations to the complement (C1q) and FcγR I binding sites of the IgGs Fc fragment render the fusion proteins incapable of antibody directed cytotoxicity (ADCC) and complement directed cytotoxicity (CDC).
Measured by its ability to stimulate human T cell proliferation in the presence of anti-CD3.
|Endotoxin Content||<0.06EU/μg protein (LAL test; Lonza).|
Reconstitute with 100 µl sterile water.
Add 1X PBS to the desired protein concentration.
|Formulation||Lyophilized from 0.2μm-filtered solution in PBS.|
|Protein Negative Control|
|Other Product Data||
NCBI reference NP_056074.1: CD275 (human)
|Declaration||Manufactured by Chimerigen.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
Avoid freeze/thaw cycles.
Centrifuge lyophilized vial before opening and reconstitution.
Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
|Product Specification Sheet|
Human B7-H2 is a member of the growing B7 family of immune costimulatory proteins. Other family members include B7-1, B7-2, B7-H1 (PD-L1), PD-L2 and B7-H3. B7 proteins are members of the immunoglobulin (Ig) superfamily, the extracellular domains contain 2 Ig-like domains and all members have short cytoplasmic domains. B7-H2 has been identified as the ligand for ICOS, a member of the CD28 family of costimulatory receptors. Human B7-H2 is expressed constitutively on resting B cells, dendritic cells and at low levels on monocytes. The B7-H2/ICOS interaction appears to play roles in T cell dependent B cell activation and Th differentiation.